mahsa fattahi

Dr. mahsa fattahi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2022 in Brazilian Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
RGReza Ghasemi
Reza Ghasemi
ELEnsieh Lotfali
Ensieh Lotfali
KRKamran Rezaei
Kamran Rezaei
SMSeyed Ataollah Madinehzad
Seyed Ataollah Madinehzad
MTMahdi Falah Tafti
Mahdi Falah Tafti
MFmahsa fattahi
mahsa fattahi

1 January 2023 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
AFAlireza Firooz
Alireza Firooz
SZShayan Zamani
Shayan Zamani
AGAliasghar Ghadrei
Aliasghar Ghadrei
AAAzin Ayatollahi
Azin Ayatollahi
PTPegah Tamimi
Pegah Tamimi
MFmahsa fattahi
mahsa fattahi
Onychomycosis is a frequent fungal nail disease that is hard to treat and, in most cases, needs long‐term therapy with oral agents. Traditionally, oral agents are favored over topical agents, but it should not be overlooked that they come with broad adverse effects and concomitant drug interactions, which can be unsuitable for many individuals. Therefore, alternative approaches need to be addressed by the medical team for numerous cases. On the other hand, local administration of antimicrobials can come as advantageous because of having a more selective site of activity, avoiding off‐target systemic adverse effects, and rapid administration at the site of infection. In this study, we are evaluating a new topical delivery method of amphotericin B. To investigate the efficacy and safety of topical nanoliposomal amphotericin B 0.4% as a possible therapeutic option, this pilot, single‐group, before‐after clinical study was conducted on 15 onychomycosis patients. The evaluation was processed during 36 weeks of follow‐up and on three endpoints of week 12, week 24, and week 36, for both clinical and mycological responses. Three patients were excluded; of the remaining 12, 50% showed a complete cure, 16.66% had an effective clinical response, 16.66% had a partial clinical response, and 16.66% showed no response at week 12. Mycological cure was calculated as 50% at week 12. At week 24, our measurements were calculated as 91.66% for complete cure, 8.33% for no response, and 91.66% for mycological cure. One patient reported nail plate detachment at week 2 but continued the topical application; follow‐up between weeks 2 and 24 showed a complete cure and regrowth of healthy nails. No other adverse effects were detected. Overall, our study suggests that topical nanoliposomal amphotericin B 0.4% is an effective treatment, which is accessible, affordable, and user‐friendly, has minimum adverse effects, and could be regarded as an alternative treatment for those ineligible for systemic therapy. This trial is registered with IRCT20150101020514N18.

12 October 2022 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ELEnsieh Lotfali
Ensieh Lotfali
RGReza Ghasemi
Reza Ghasemi
NMNiloofar Masoumi
Niloofar Masoumi
DMDanial Molavizadeh
Danial Molavizadeh
SSSara Sadeghi
Sara Sadeghi
MFmahsa fattahi
mahsa fattahi
Background: Otomycosis is defined as a superficial fungal infection, accounting for about 10% of infectious otitis externa cases. Objectives: This study investigated patients with suspicious symptoms through the examination of their demographic information, isolate etiological agents, and in vitro antifungal susceptibility patterns. Methods: The samples of 170 patients with otitis externa symptoms were collected and confirmed for otomycosis by mycological examination (e.g., potassium hydroxide, methylene blue staining, and fungal culture) and molecular sequencing. In vitro antifungal susceptibility tests against miconazole, fluconazole, itraconazole, voriconazole, posaconazole, amphotericin B, and caspofungin were performed according to the Clinical and Laboratory Standards Institute (M27-A3/S4 and M38-A2). Results: Out of 170 patients, 145 subjects (85.29%) showed positive mycological findings. In this study, 55.8% of the patients were male, and the most common age group affected was 50 - 59 years (26.2%). Hearing loss and pruritus were the most common clinical manifestations. The most common occupation was being a housewife (47.5%), and most cases occurred during the winter (40%). Aspergillus niger was the most common species, followed by Aspergillus fumigatus, Candida albicans, and Candida glabrata. Caspofungin showed the highest activity against Aspergillus and Candida isolates; nevertheless, itraconazole demonstrated the lowest activity against Aspergillus isolates. Fluconazole showed the weakest power against Candida species. Conclusions: Due to climatic conditions, humidity, and dust, otomycosis has a high occurrence in Iran. Although otomycosis needs long-term antifungal therapy and recurrence is high in some cases, it is rarely life-threatening, and eardrop antifungals are usually enough to eradicate the infection. Local information about the antifungal pattern is useful for the control, prevention, and treatment of otomycosis.

7 May 2024 in International Journal of Dermatology
Verified
Journal Article
Closed access
PTPegah Tamimi
Pegah Tamimi
MFmahsa fattahi
mahsa fattahi
AFAlireza Firooz
Alireza Firooz
AGAliasghar Ghaderi
Aliasghar Ghaderi
AAAzin Ayatollahi
Azin Ayatollahi
AAAhmed Alkhen
Ahmed Alkhen

2 December 2021 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZYZeynab Yassin
Zeynab Yassin
FSFariba Shirvani
Fariba Shirvani
MFmahsa fattahi
mahsa fattahi
Background: Candida albicans is the predominant yeast reported from human infection. Non-albicans Candida species have been recently developed as medically vital fungi. Therefore, it is essential to detect and identify the pathogens at the species level to prescribe appropriate treatment. Methods: This study assessed two complementary methods, including real-time polymerase chain reaction-high resolution melt (PCR-HRM) and polymerase chain reaction-restriction fragment length morphism (PCR-RFLP) with standard PCR and Sanger sequencing as the benchmark. Results: In total, 66 samples were tested, and two newly-advanced assays were more effective and displayed comprehensive concordance (66/66, 100%) with Sanger sequencing outcomes. Moreover, accurate and economical tests were positively advanced by real-time PCR-HRM for C. albicans and C. parapsilosis complexes. Conclusions: Given the number of studies performed on the comparison of sensitivity and specificity of phenotypic and genotypic methods to diagnose and identify invasive fungal pathogens and the findings of this study, it could be stated that the correlative PCR-HRM and PCR-RFLP methods were effectively advanced as substitutes for conventional Sanger sequencing for the reasonable identification. However, supplementary evaluations and confirming studies should be carried out with a broad range of samples to standardize this method for routine application in medical laboratories.

1 August 2021 in Recent Advances in Anti-Infective Drug Discovery
Verified
Journal Article
Closed access
PDF file
ELEnsieh Lotfali
Ensieh Lotfali
MFmahsa fattahi
mahsa fattahi
RGReza Ghasemi
Reza Ghasemi
FZFarzan Zakermashhadi
Farzan Zakermashhadi
MSMohammad Shafiei
Mohammad Shafiei
MRMohammad Mahdi Rabiei
Mohammad Mahdi Rabiei
Introduction: Onychomycosis, also called tinea unguium, is a common fungal infection affecting the nails. After dermatophytes, Candida species are recognized as second-line pathogens responsible for this infection. The treatment of onychomycosis requires a long time and is associated with high rates of recurrence. Antifungal medicines conjugated with gold (Au-NP) nanoparticle are the possible platforms for the reduction of drug resistance. Methods: In the present study, we reported the in-vitro antifungal activity of itraconazole (ITZ) – Au conjugates, time-kill studies, and biofilm-producing ability of six ITZ-resistant C. glabrata. Results: 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium bromide (MTT) quantitative results revealed that four out of six resistant isolates studied able to form biofilms in vitro. ITZ-Au conjugates were more effective than ITZ or Au nanoparticle alone, and the time-kill tests pointed to the suitable effect of ITZ-Au conjugate. Conclusion: The present study concluded that ITZ-Au conjugates have an inhibitory effect on the biofilm of resistant C. glabrata isolates. Further studies are needed to compare the ex-vivo onychomycosis model.